Business Wire

Mitsui Chemicals to Launch MILASTOMER™ Production in North America

Del

Mitsui Chemicals, Inc. (TOKYO:4183)(President & CEO: Tsutomu Tannowa) has decided to set up a new production facility for MILASTOMER™ thermoplastic olefin elastomer at the Ohio-plant of its U.S. subsidiary Advanced Composites, Inc. (President: Keiji Shite).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180326006195/en/

New facility site at Advanced Composites, Inc. (Photo: Business Wire)

New facility site at Advanced Composites, Inc. (Photo: Business Wire)

 

Overview of New Production Facility

1. Product   MILASTOMER™
2. Location Advanced Composites, Inc., Ohio plant
3. Capacity 1 production line; 6,000 tons/year
4. Schedule (tentative)   Construction begins January 2019. Completion in June. Operations commence in October.
 

The primary ingredients of MILASTOMER™ thermoplastic olefin elastomer are olefin rubber and olefin resin. With its low density, light weight and excellent moldability, Mitsui Chemicals markets the soft resin worldwide as a substitute for vinyl chloride and vulcanized rubber. The many uses for MILASTOMER™ include auto parts, building gaskets, toothbrushes, golf club grips and more. Global demand is projected to rise, primarily for applications such as automotive interior covers, weather strips, air bag covers and steering bellows. Demand for use in automotive interior covers is expected to expand especially in North America.

Mitsui Chemicals currently owns production centers in Japan, Europe and China. The new facility in the U.S. will address growing demand in North America and serve as the company's fourth production base worldwide. Mitsui Chemicals America, Inc. will sell MILASTOMER™ in North America, while Advanced Composites, Inc. will handle production.

As Mitsui Chemicals is working to further strengthen its MILASTOMER™ business, the company will provide a safe and steady supply by correctly gauging global growth in demand so as to continue expanding business.

 

Overview of Advanced Composites, Inc.

1. Established   June 1986
2. Capital and Stakes

US$14,100,000
Mitsui Chemicals America, Inc. (wholly owned by Mitsui Chemicals): 59.8%
Prime Polymer Co. Ltd.: 3.0%
Mitsui & Co. Ltd. (incl. Mitsui Plastics, Inc.): 27.0%
Marubeni America Corporation: 10.2%

3. President Keiji Shite

4. Head Office and Plants

Head Office: Ohio
Plants: Ohio, Tennessee

5. Business  

Production, sale and research of polypropylene compounds
Contracted production of MILASTOMER™ (to be added October 2019)

Contact information

Mitsui Chemicals, Inc.
Takashi Kawamoto, +81-3-6253-2100
Corporate Communications Division
takashi.kawamoto@mitsuichemicals.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Huawei Rewrites the Rules of Photography with Groundbreaking HUAWEI P30 Series26.3.2019 16:04:00 CETPressemelding

During an exclusive launch event today at the Paris Convention Center, Huawei Consumer Business Group (BG) unveiled the HUAWEI P30 and HUAWEI P30 Pro. The HUAWEI P30 Series builds on the HUAWEI P Series DNA in design and photography and is the company’s most advanced series of smartphone cameras. These devices feature the innovative HUAWEI SuperSpectrum Sensor, an optical SuperZoom Lens, a new HUAWEI Time of Flight (ToF) Camera, and enhanced optical and AI image stabilization technology. With these revolutionary technologies, the HUAWEI P30 and HUAWEI P30 Pro capture incredible photos and videos in every scenario. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005752/en/ HUAWEI P30 Series (Photo: Business Wire) Richard Yu, CEO of Huawei Consumer BG, said, “the HUAWEI P30 Series is a fundamental breakthrough after decades of digital camera technology development; it will rewrite the rules and reshape everyone’s percepti

Takeda Presents New Data at the Endocrine Society’s 2019 Annual Meeting about the Patient Burden and Long-Term Impact of Chronic Hypoparathyroidism26.3.2019 15:01:00 CETPressemelding

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) this week shared new data revealing the burden of chronic hypoparathyroidism on patients and caregivers, as well as potential long-term risks of renal and cardiovascular complications that patients treated with conventional therapy may experience. Six-year results from the open-label long-term safety and efficacy RACE study were also announced. Data was presented at the Endocrine Society’s 2019 Annual Meeting (ENDO) from 23–26 March in New Orleans, Louisiana, USA. “Results from the Burden of Illness Global Survey in 13 countries reveal the extent of the impact hypoparathyroidism has on patients and their caregivers throughout their daily lives,” said John Bilezikian M.D., Professor of Medicine at the Columbia University Irving Medical Center, New York, NY, USA. “This offers important insights and enables us to take a more holistic approach in the management of these patients due to a greater understanding of the poten

LEO Pharma Standardizes on Veeva Development Cloud to Speed Drug Development26.3.2019 14:58:00 CETPressemelding

Veeva Systems (NYSE:VEEV) today announced that LEO Pharma, a global leader in medical dermatology, selected Veeva Development Cloud applications to help drive end-to-end business processes across product development. The company will utilize the Vault Clinical, Vault RIM, and Vault Quality suites to unify drug development on a single cloud platform. With Veeva Development Cloud, LEO Pharma can bring together applications for clinical, regulatory, and quality for even greater efficiency and compliance throughout the product development lifecycle. “LEO Pharma R&D has embarked on an ambitious strategy for 2025, which will pave the way for our ambitions to continuously pioneer dermatology. This requires that we are able to drive science globally, whilst at the same time securing timely delivery on our pipeline,” said Kim Kjøller, executive vice president of global research and development at LEO Pharma. “Veeva Development Cloud gives us a unified platform that can enable us to maximize eff

Keio Plaza Hotel Tokyo Hosts Japanese Sword Culture, Armor Exhibition – “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans”26.3.2019 14:05:00 CETPressemelding

Keio Plaza Hotel Tokyo (KPH), one of Japan’s most prestigious international hotels located in Shinjuku, Tokyo, will host a special exhibition entitled “Japan’s Soul and Beauty of Swords and Armor by Legendary Artisans” displaying beautiful Japanese swords and armor from April 25 (Thursday) to June 27 (Thursday), 2019 in the 3rd floor lobby of our Hotel. This exhibition is part of our series of cultural programs designed to introduce various aspects of Japanese culture to our guests visiting the Hotel from over 100 different countries around the world. Various precious and old swords and armor made during the Heian Period (794-1185) and other periods of Japanese history will be displayed, along with “tsuba” (Sword handle guards separating the handle from the blade) and other ornate sword fittings. On May 14, two masters of sword-drawing from Ryushin Shouchi School will give a live performance in the Main lobby from 5:00 p.m. This press release features multimedia. View the full release

Andersen Global Enters Qatar26.3.2019 13:30:00 CETPressemelding

Andersen Global today announced a collaborating agreement in Qatar with Al-Khalifa Law, a leading Doha-based law firm. The collaboration is Andersen Global’s first in Qatar and is part of the organization’s continued growth in the Middle East. Al-Khalifa Law was founded 20 years ago and established itself as a premier firm in the region. The team at Al-Khalifa Law has diversified, deep experience providing services in a wide variety of business sectors, such as commercial contracts, taxation, employment, real estate and retail, intellectual property, dispute resolution and litigation and arbitration. “A collaboration with Andersen Global, which brings with it a culture of stewardship, transparency, and providing best-in-class services, was an obvious decision for us,” said Hamzeh Abdelhady, Office Managing Director of Al-Khalifa Law. “We will be able to continue providing quality services in the market and bring a premier, seamless association of experts throughout the world directly t

Vivior’s System Cleared for CE Mark – Market Introduction This Year in Europe26.3.2019 13:18:00 CETPressemelding

Vivior has cleared their system as a Class I medical device and is planning the market introduction later this year in Switzerland and the European Union. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190326005594/en/ The Visual Behavior Monitor (Photo: Business Wire) Vivior has notified Swissmedic about their product, the Visual Behavior Monitor, and fulfills all requirements for a medical device Class I according to the Medical Device Directive (MDD). With this important step, Vivior is now allowed to sell their system in Switzerland and the European Union. Mario Stark, CEO at Vivior, explains: “We are happy to be able to start market introduction and will, in a first step, work with selected clinics in Europe.” Prof. Michael Mrochen, Chairman of the Board of Directors, adds: “This constitutes an important milestone in the development of the Vivior system. We are now ready to support eye care professionals in offering the